for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

InspireMD Inc

NSPR.A

Latest Trade

0.46USD

Change

-0.01(-1.96%)

Volume

91,531

Today's Range

0.46

 - 

0.48

52 Week Range

0.39

 - 

5.30

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
0.47
Open
0.48
Volume
91,531
3M AVG Volume
96.01
Today's High
0.48
Today's Low
0.46
52 Week High
5.30
52 Week Low
0.39
Shares Out (MIL)
33.36
Market Cap (MIL)
15.82
Forward P/E
-0.36
Dividend (Yield %)
--

Next Event

Q2 2020 InspireMD Inc Earnings Call

Latest Developments

More

InspireMD Q2 Loss Per Share $0.20

InspireMD Announces Pricing Of $10 Mln Underwritten Public Offering

Inspiremd Inc Files For Offering Of Up To $11.5 Million Shares Of Common Stock And Warrants

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About InspireMD Inc

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Industry

Medical Equipment & Supplies

Contact Info

4 Menorat Hamaor St.

TEL AVIV-YAFO, MA

6744832

Israel

+1.857.4536553

http://www.inspiremd.com/

Executive Leadership

Paul S. Stuka

Chairman of the Board

Marvin L. Slosman

Chief Executive Officer

Isaac Blech

Independent Vice Chairman of the Board

Craig Shore

Chief Financial Officer, Chief Administrative Officer, Treasurer and Secretary

Agustin V. Gago

Executive Vice President, Chief Commercial Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-4.788

2020(E)

-1.300
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.65
Price To Book (MRQ)
0.59
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-144.42
Return on Equity (TTM)
-101.03

Latest News

Latest News

BRIEF-InspireMD Announces Underwriter Exercise Of Over-Allotment Option In Full And Closing Of $11.5 Million Follow-On Underwritten Public Offering

* INSPIREMD, INC. ANNOUNCES UNDERWRITER EXERCISE OF OVER-ALLOTMENT OPTION IN FULL AND CLOSING OF $11.5 MILLION FOLLOW-ON UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-InspireMD Announces Pricing Of $10 Mln Underwritten Public Offering

* INSPIREMD, INC. ANNOUNCES PRICING OF $10 MILLION UNDERWRITTEN PUBLIC OFFERING

BRIEF-Inspiremd Inc Files For Offering Of Up To $11.5 Million Shares Of Common Stock And Warrants

* INSPIREMD INC FILES FOR OFFERING OF UP TO $11.5 MILLION SHARES OF COMMON STOCK AND WARRANTS – SEC FILING Source text - https://bit.ly/2zz3jKa Further company coverage:

BRIEF-Inspiremd Announces First Quarter 2020 Financial Results

* QTRLY REVENUES $1 MILLION VERSUS $415,000 Source text for Eikon: Further company coverage:

BRIEF-Inspiremd Inc - Approved A 50% Decrease In Annual Cash Compensation For Non-Employee Directors - SEC Filing

* INSPIREMD INC - APPROVED A 50% DECREASE IN ANNUAL CASH COMPENSATION FOR NON-EMPLOYEE DIRECTORS - SEC FILING

BRIEF-Inspiremd Announces Fourth Quarter And Year-End 2019 Financial Results

* INSPIREMD ANNOUNCES FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS

BRIEF-InspireMD Receives Regulatory Approval For CGuard EPS, MGuard Prime In Ecuador

* INSPIREMD RECEIVES REGULATORY APPROVAL FOR BOTH CGUARD EPS AND MGUARD PRIME IN ECUADOR Source text for Eikon: Further company coverage:

BRIEF-Inspiremd Q1 Loss Per Share $1.08

* INSPIREMD REPORTS 132% INCREASE IN CGUARD™ EPS SALES FOR THE FIRST QUARTER OF 2018

BRIEF-InspireMD Cleared To Commercialize Cguard EPS And Mguard Prime In Vietnam

* INSPIREMD ANNOUNCES REGULATORY APPROVAL AND REIMBURSEMENT TO COMMERCIALIZE BOTH CGUARD EPS™ AND MGUARD™ PRIME PRODUCTS IN VIETNAM Source text for Eikon: Further company coverage:

BRIEF-InspireMD Announces Pricing Of $5 Mln Public Offering Of Common Stock

* INSPIREMD, INC. ANNOUNCES PRICING OF $5.0 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Inspiremd Announces Proposed Public Offering Of Common Stock

* INSPIREMD, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Inspiremd Receives Regulatory Approval For Both Cguard™ EPS And Mguard Prime™ In Peru

* INSPIREMD RECEIVES REGULATORY APPROVAL FOR BOTH CGUARD™ EPS AND MGUARD PRIME™ IN PERU Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Inspiremd Announces Pricing Of Public Offering Of Common Stock

* INSPIREMD, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-InspireMD Announces Proposed Public Offering Of Common Stock

* INSPIREMD, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-InspireMD Enters Distribution, Sales & Marketing Agreement For Cguard EPS In South Korea

* INSPIREMD ANNOUNCES EXCLUSIVE DISTRIBUTION, SALES AND MARKETING AGREEMENT FOR CGUARD EPS IN SOUTH KOREA

BRIEF-InspireMD Inc Files For Mixed Shelf Of Upto $30 Mln

* INSPIREMD INC FILES FOR MIXED SHELF OF UPTO $30 MILLION - SEC FILING Source: (http://bit.ly/2CAh5b6) Further company coverage:

BRIEF-Inspiremd Announces Q4 Loss Per Share $7.38

* INSPIREMD ANNOUNCES FOURTH QUARTER AND YEAR-END 2017 RESULTS; CGUARD™ EPS FOURTH QUARTER SALES INCREASE 211% VERSUS SAME PERIOD LAST YEAR

BRIEF-InspireMD Sees Q4 2017 Sales About $833,000

* SEES Q4 2017 SALES ABOUT $833,000 Source text for Eikon: Further company coverage:

BRIEF-InspireMD Announces Regulatory Approval Of CGuard EPS In India

* INSPIREMD ANNOUNCES REGULATORY APPROVAL OF CGUARD EPS IN INDIA; SIGNS AGREEMENT WITH LEADING INDIAN MEDICAL DEVICE DISTRIBUTOR

BRIEF-Sabby Management​ Reports 9.99 Pct Passive Stake In InspireMD

* SABBY MANAGEMENT REPORTS 9.99 PERCENT PASSIVE STAKE IN INSPIREMD AS OF DEC 12 - SEC FILING Source text: (http://bit.ly/2zcFtkG) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up